Overview
Assessing the Value of Neurological Imaging in RRMS to Best Evaluate Neurodegeneration and Patient Outcomes
Morning Satellite Symposium
Registration is closed for this activity.
This educational activity is designed for physicians, pharmacists, nurses, scientists, and researchers examining the advances in research and treatment of MS on the care of patients.
MS is a rapidly advancing field, not only in terms of the evolution of disease-modifying therapies, but also with respect to neurobiological advancements in myelin repair. Additionally, refinement is being made to existing MRI measures to provide clinicians with clinically practical approaches to the management of MS. Clinicians treating MS patients may not be familiar with these advancements and would benefit from expert recommendations, guidance, and training to understand how MRI may be used to assess the risks and benefits of MS therapies, and track disease progression, in order to optimize disease management.
Upon completion of this activity, participants will be able to:
- Assess if and how available and emerging MS therapies impact neurodegeneration
- Review how MRI can be used to assess brain atrophy to identify patients with MS at the highest risk for decline
- Explain how brain volume loss may be another outcome measure for assessing disease progression and disability in patients with MS
1500 Masters Boulevard
Orlando, FL 33896 USA
Click here to view location map
Comment: Osceola Ballroom C & D
• Current, clinical applications of MRI in MS
• Brain atrophy in MS
• Neuroprotection and repair in MS
Professor and Vice Chair (Clinical Affairs)
Director, MS Comprehensive Care
Department of Neurology
Stony Brook University Medical Center
Stony Brook, NY
Department of Radiology and Medicine (Neurology)
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.